LifeSci Capital Reaffirms Their Hold Rating on Better Therapeutics, Inc. (BTTX)

LifeSci Capital analyst Rahul Rakhit maintained a Hold rating on Better Therapeutics, Inc. (BTTX – Research Report) today. The company’s shares opened today at $0.15.

Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Orchestra BioMed Holdings, and Better Therapeutics, Inc.. According to TipRanks, Rakhit has an average return of -61.7% and a 0.00% success rate on recommended stocks.

Currently, the analyst consensus on Better Therapeutics, Inc. is a Moderate Buy with an average price target of $6.00.

See today’s best-performing stocks on TipRanks >>

BTTX market cap is currently $7.16M and has a P/E ratio of -0.13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Better Therapeutics, Inc. (BTTX) Company Description:

Mountain Crest Acquisition Corp II is a blank check company.

Read More on BTTX:

• Better Therapeutics reports Q3 EPS (15c), consensus (21c)
• Better Therapeutics announces topline findings from AspyreRx analysis
• Better Therapeutics’ LivVita study met primary endpoint by reducing liver fat
• Better Therapeutics completes enrollment of 1,000 participates in two studies